Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Chem Biol Drug Des ; 98(4): 507-521, 2021 10.
Article in English | MEDLINE | ID: mdl-34143939

ABSTRACT

Among the compounds of natural origin, diterpenes have proved useful as drugs for the treatment of cancer. Marine organisms, such as soft corals and algae, are a promising source of diterpenes, being a rich and unexplored source of cytotoxic agents. This study evaluated a library of 32 natural and semisynthetic marine diterpenes, including briarane, cembrane, and dolabellane nuclei, with the aim of determining their cytotoxicity against three human cancer cell lines (A549, MCF7, and PC3). The three most active compounds were submitted to a flow cytometry analysis in order to determine induction of apoptosis against the A549 cell line. An NMR analysis was conducted to determine and evaluate the interactions between active diterpenes and tubulin. These interactions were characterized by a computational study using molecular docking and MD simulations. With these results, two cembrane and one chlorinated briarane diterpenes were active against the three human cancer cell lines, induced apoptosis in the A549 cell line, and showed interactions with tubulin preferably at the taxane-binding site. This study is a starting point for the identification and optimization of the marine diterpenes selected for better antitumor activities. It also highlights the power of integrating NMR studies, computational predictions, and in vitro assays in the search for compounds with antitumor activity.


Subject(s)
Anthozoa/chemistry , Antineoplastic Agents/chemistry , Biological Products/chemistry , Complex Mixtures/chemistry , Diterpenes/chemistry , Small Molecule Libraries/chemistry , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Biological Products/pharmacology , Cell Line, Tumor , Complex Mixtures/pharmacology , Computational Biology , Diterpenes/pharmacology , Drug Screening Assays, Antitumor , Halogenation , Humans , Magnetic Resonance Spectroscopy , Models, Molecular , Small Molecule Libraries/pharmacology , Structure-Activity Relationship
2.
Neurosci Lett ; 750: 135764, 2021 04 17.
Article in English | MEDLINE | ID: mdl-33621639

ABSTRACT

Alzheimer's disease (AD) is the main cause of dementia in the world. Studies of human AD brains show abnormalities in the white matter and reduction of myelin and oligodendrocyte markers. It has been proposed that oligodendrocyte progenitor cells (OPCs) present in the adult brain are a potential source for re-myelination, through proliferation and differentiation into mature oligodendrocytes. Bexarotene, a Retinoid X Receptor agonist, has been demonstrated to reverse behavioral deficits and to improved synaptic transmission and plasticity in murine models of AD, which was associated with the reduction of soluble Aß peptides. In the present study, we analyzed changes in the expression of oligodendrocyte lineage markers following oral administration of Bexarotene in a very old (24-month-old) triple transgenic mouse model of AD (3xTg-AD), for which early demyelination changes have been previously described. Bexarotene increased the expression of OPCs and intermediate oligodendrocyte progenitors (Olig2+ and O4+), and increased the number of mitotic (O4+) and myelinating mature (MBP+) oligodendrocytes. We clearly show that Bexarotene promotes re-myelination which might be important for the previously observed cognitive improvement of 3xTg-AD mice treated with this drug.


Subject(s)
Alzheimer Disease/metabolism , Bexarotene/pharmacology , Myelin Sheath/metabolism , Neuroprotective Agents/pharmacology , Oligodendroglia/drug effects , Retinoid X Receptors/agonists , Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Cell Proliferation , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Female , Hippocampus/cytology , Hippocampus/drug effects , Hippocampus/metabolism , Male , Mice , Mice, Inbred C57BL , Oligodendroglia/metabolism , Oligodendroglia/physiology , Presenilin-1/genetics , tau Proteins/genetics
3.
Mech Ageing Dev ; 192: 111360, 2020 12.
Article in English | MEDLINE | ID: mdl-32976914

ABSTRACT

Recently, mutations in the RNA polymerase III subunit A (POLR3A) have been described as the cause of the neonatal progeria or Wiedemann-Rautenstrauch syndrome (WRS). POLR3A has important roles in transcription regulation of small RNAs, including tRNA, 5S rRNA, and 7SK rRNA. We aim to describe the cellular and molecular features of WRS fibroblasts. Cultures of primary fibroblasts from one WRS patient [monoallelic POLR3A variant c.3772_3773delCT (p.Leu1258Glyfs*12)] and one control patient were cultured in vitro. The mutation caused a decrease in the expression of wildtype POLR3A mRNA and POLR3A protein and a sharp increase in mutant protein expression. In addition, there was an increase in the nuclear localization of the mutant protein. These changes were associated with an increase in the number and area of nucleoli and to a high increase in the expression of pP53 and pH2AX. All these changes were associated with premature senescence. The present observations add to our understanding of the differences between Hutchinson-Gilford progeria syndrome and WRS and opens new alternatives to study cell senesce and human aging.


Subject(s)
Fetal Growth Retardation , Fibroblasts , Progeria , RNA Polymerase III , Tumor Suppressor Protein p53/metabolism , Cell Nucleolus/physiology , Cells, Cultured , Cellular Senescence/physiology , DNA Damage , Fetal Growth Retardation/genetics , Fetal Growth Retardation/pathology , Fibroblasts/physiology , Fibroblasts/ultrastructure , Gene Expression , Humans , Mutation , Progeria/genetics , Progeria/pathology , RNA Polymerase III/genetics , RNA Polymerase III/metabolism , RNA, Ribosomal, 5S/metabolism
4.
Mar Drugs ; 18(1)2019 Dec 18.
Article in English | MEDLINE | ID: mdl-31861453

ABSTRACT

The Caribbean soft coral Erythropodium caribaeorum is a rich source of erythrolides-chlorinated briarane diterpenoids. These compounds have an ecological role as feeding deterrents, with a wide variation in their composition depending on the location where the sample is collected. In Colombia, this soft coral can be found at different locations in the Caribbean Sea including Santa Marta, Islas del Rosario, and Providencia-three environmentally different coral reef areas in the south and southwest Caribbean Sea. In order to evaluate differences in erythrolide composition, the metabolic profiles of samples from each of these locations were analyzed by HPLC-MS. Principal component analysis showed changes in the diterpene composition according to the sample origin. Diterpenes from samples collected at each location were isolated to describe the three chemotypes. The chemotype from Santa Marta was highly diverse, with the new erythrolides W and X together with eight known erythrolides. The sample from Islas del Rosario showed a low diversity chemotype constituted by high amounts of erythrolide A and B. The chemotype from Providencia showed low chemical diversity with only two main compounds-erythrolide V and R. Evaluation of cytotoxic activity against the human cancer cell lines PC-3, MCF7, and A549 showed erythrolides A and B as the more active compounds with IC50 values in the range from 2.45 to 30 µM.


Subject(s)
Anthozoa/chemistry , Metabolome , Animals , Anthozoa/metabolism , Caribbean Region , Colombia , Coral Reefs , Diterpenes/chemistry , Humans
5.
PLoS One ; 14(10): e0223578, 2019.
Article in English | MEDLINE | ID: mdl-31596896

ABSTRACT

INTRODUCTION: Bexarotene, a retinoid X receptor agonist, improves cognition in murine models of Alzheimer's disease (AD). This study evaluated the effects of bexarotene on pathological and electrophysiological changes in very old triple transgenic AD mice (3xTg-AD mice). METHODS: 24-month-old 3xTg-AD mice were treated with bexarotene (100 mg/kg/day for 30 days). The Morris water maze was used to evaluate spatial memory; immunofluorescence and confocal microscopy were used to evaluate pathological changes; and in vivo electrophysiological recordings were used to evaluate basal transmission and plasticity in the commissural CA3-CA1 pathway. RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity. DISCUSSION: These results indicate that bexarotene-induced improvement in cognition is due to multiple changes that contribute to recovery of synaptic plasticity.


Subject(s)
Alzheimer Disease/drug therapy , Bexarotene/therapeutic use , Hippocampus/drug effects , Neuroprotective Agents/therapeutic use , Alzheimer Disease/genetics , Animals , Apolipoproteins E/metabolism , Bexarotene/pharmacology , DNA-Binding Proteins/metabolism , Female , Gliosis , Hippocampus/growth & development , Hippocampus/metabolism , Hippocampus/physiopathology , Male , Maze Learning , Mice , Nerve Tissue Proteins/metabolism , Neuroglia/metabolism , Neuronal Plasticity , Neuroprotective Agents/pharmacology , Synaptic Transmission
6.
Cancers (Basel) ; 11(9)2019 Sep 09.
Article in English | MEDLINE | ID: mdl-31505859

ABSTRACT

X-linked inhibitor of apoptosis protein (XIAP) is an emerging crucial therapeutic target in cancer. We report on the discovery and characterisation of small organic molecules from Piper genus plants exhibiting XIAP antagonism, namely erioquinol, a quinol substituted in the 4-position with an alkenyl group and the alkenylphenols eriopodols A-C. Another isolated compound was originally identified as gibbilimbol B. Erioquinol was the most potent inhibitor of human cancer cell viability when compared with gibbilimbol B and eriopodol A was listed as intermediate. Gibbilimbol B and eriopodol A induced apoptosis through mitochondrial permeabilisation and caspase activation while erioquinol acted on cell fate via caspase-independent/non-apoptotic mechanisms, likely involving mitochondrial dysfunctions and aberrant generation of reactive oxygen species. In silico modelling and molecular approaches suggested that all molecules inhibit XIAP by binding to XIAP-baculoviral IAP repeat domain. This demonstrates a novel aspect of XIAP as a key determinant of tumour control, at the molecular crossroad of caspase-dependent/independent cell death pathway and indicates molecular aspects to develop tumour-effective XIAP antagonists.

7.
Epigenomics ; 10(11): 1365-1382, 2018 11.
Article in English | MEDLINE | ID: mdl-30324800

ABSTRACT

OBJECTIVE: To study DNA methylation patterns of cortical pyramidal layers susceptible to late-onset Alzheimer's disease (LOAD) neurodegeneration. METHODS: Laser-assisted microdissection to select pyramidal layers' cells in frontal cortex of 32 human brains (18 LOAD) and Infinium DNA Methylation 450K analysis were performed to find differential methylated positions and regions, in addition to the corresponding gene set functional enrichment analyses. RESULTS: Differential hypermethylation in several genomic regions and genes mainly in HOXA3, GSTP1, CXXC1-3 and BIN1. The functional enrichment analysis revealed genes significantly related to oxidative-stress and synapsis. CONCLUSION: The present results indicate the differentially methylated genes related to neural projections, synapsis, oxidative stress and epigenetic regulator genes and represent the first epigenome of cortical pyramidal layers in LOAD.


Subject(s)
Alzheimer Disease/genetics , DNA Methylation , Frontal Lobe/metabolism , Adaptor Proteins, Signal Transducing/genetics , Aged , Aged, 80 and over , DNA-Binding Proteins/genetics , Female , Glutathione S-Transferase pi/genetics , Homeodomain Proteins/genetics , Humans , Laser Capture Microdissection , Male , Nuclear Proteins/genetics , Oxidative Stress , Pyramidal Cells/metabolism , Synaptic Transmission , Trans-Activators , Tumor Suppressor Proteins/genetics
9.
Adv Exp Med Biol ; 949: 287-310, 2016.
Article in English | MEDLINE | ID: mdl-27714695

ABSTRACT

During development and through adulthood, differentiation of diverse cell types is controlled by specific genetic and molecular programs for which transcription factors are master regulators of gene expression. Here, we present an overview of the role of nuclear receptors and their selective pharmacological modulators in oligodendrocytes linage, their role in myelination and remyelination and their potential use as a therapeutic strategy for demyelinating diseases. We discuss several aspects of nuclear receptors including: (1) the biochemistry of nuclear receptors superfamily; (2) their role on stem cells physiology, focusing in differentiation and cell removal; (3) the role of nuclear receptor in the oligodendrocytes cell linage, from oligodendrocyte progenitors cells to mature myelinating cells; and (4) the therapeutics opportunities of nuclear receptors for specific demyelinating diseases.


Subject(s)
Adrenoleukodystrophy/genetics , Alzheimer Disease/genetics , Oligodendroglia/metabolism , Receptors, Retinoic Acid/genetics , Stem Cells/metabolism , Adrenoleukodystrophy/drug therapy , Adrenoleukodystrophy/metabolism , Adrenoleukodystrophy/pathology , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , COUP Transcription Factors/agonists , COUP Transcription Factors/genetics , COUP Transcription Factors/metabolism , Cell Differentiation , Cell Lineage , Drugs, Investigational/therapeutic use , Gene Expression Regulation , Humans , Liver X Receptors/agonists , Liver X Receptors/genetics , Liver X Receptors/metabolism , Neuroprotective Agents/therapeutic use , Oligodendroglia/drug effects , Oligodendroglia/pathology , Orphan Nuclear Receptors , Peroxisome Proliferator-Activated Receptors/agonists , Peroxisome Proliferator-Activated Receptors/genetics , Peroxisome Proliferator-Activated Receptors/metabolism , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Retinoic Acid/agonists , Receptors, Retinoic Acid/metabolism , Stem Cells/drug effects , Stem Cells/pathology
10.
Neurosci Lett ; 621: 15-21, 2016 05 16.
Article in English | MEDLINE | ID: mdl-27057732

ABSTRACT

The vascular hypothesis of Alzheimer's disease postulates that disruption of the brain microvasculature is important for the accumulation of amyloid beta and increased neuroinflammation. Liver X Receptor agonist, GW3965, has been demonstrated to successfully modulate neuroinflammation and lipid metabolism in murine models of AD. This is partially due to increased expression of ApoE levels and increased mobility of endothelial progenitor cells. This paper analyzes changes in the neurovascular unit and in astrocytes and microglia markers following oral administration of GW3965 in a very old triple transgenic AD mice (3xTg-AD mice). We found that astrogliosis, but not activation of microglia, decreased in very old (24 months) 3xTg-AD mice treated with GW965. In addition, GW3965 increased LRP1 levels in neuron-like cells and partially restored microvascular morphology by decreasing tortuosity and increasing length as shown by Lectin immunostaining. Interestingly, these changes were associated with decreased Aß in blood vessels. In conclusion, short-term treatment of 3xTg-AD mice with GW3965 restored microvascular architecture which may be important in the cognitive improvement previously shown.


Subject(s)
Alzheimer Disease/metabolism , Hippocampus/blood supply , Hippocampus/metabolism , Liver X Receptors/agonists , Microvessels/metabolism , Aging , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Animals , Astrocytes/metabolism , Benzoates/pharmacology , Benzylamines/pharmacology , Biomarkers/metabolism , Glial Fibrillary Acidic Protein/metabolism , Hippocampus/drug effects , Liver X Receptors/metabolism , Mice , Mice, Transgenic , Microglia/metabolism , Microvessels/drug effects , Microvessels/pathology , Neurons/metabolism
11.
PLoS One ; 10(12): e0145467, 2015.
Article in English | MEDLINE | ID: mdl-26720273

ABSTRACT

Alzheimer's disease (AD) is the major cause of dementia worldwide. The pharmacological activation of nuclear receptors (Liver X receptors: LXRs or Retinoid X receptors: RXR) has been shown to induce overexpression of the ATP-Binding Cassette A1 (ABCA1) and Apolipoprotein E (ApoE), changes that are associated with improvement in cognition and reduction of amyloid beta pathology in amyloidogenic AD mouse models (i.e. APP, PS1: 2tg-AD). Here we investigated whether treatment with a specific LXR agonist has a measurable impact on the cognitive impairment in an amyloid and Tau AD mouse model (3xTg-AD: 12-months-old; three months treatment). The data suggests that the LXR agonist GW3965 is associated with increased expression of ApoE and ABCA1 in the hippocampus and cerebral cortex without a detectable reduction of the amyloid load. We also report that most cells overexpressing ApoE (86±12%) are neurons localized in the granular cell layer of the hippocampus and entorhinal cortex. In the GW3965 treated 3xTg-AD mice we also observed reduction in astrogliosis and increased number of stem and proliferating cells in the subgranular zone of the dentate gyrus. Additionally, we show that GW3965 rescued hippocampus long term synaptic plasticity, which had been disrupted by oligomeric amyloid beta peptides. The effect of GW3965 on synaptic function was protein synthesis dependent. Our findings identify alternative functional/molecular mechanisms by which LXR agonists may exert their potential benefits as a therapeutic strategy against AD.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Orphan Nuclear Receptors/metabolism , ATP Binding Cassette Transporter 1/metabolism , Alzheimer Disease/drug therapy , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Animals , Apolipoproteins E/metabolism , Benzoates/pharmacology , Benzoates/therapeutic use , Benzylamines/pharmacology , Benzylamines/therapeutic use , Biomarkers/metabolism , Cell Proliferation/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Cognition Disorders/complications , Cognition Disorders/drug therapy , Cognition Disorders/metabolism , Cognition Disorders/physiopathology , DNA-Binding Proteins , Dentate Gyrus/drug effects , Dentate Gyrus/metabolism , Dentate Gyrus/pathology , Excitatory Postsynaptic Potentials/drug effects , Female , Fluorescent Antibody Technique , Gliosis/complications , Gliosis/pathology , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Liver X Receptors , Long-Term Potentiation/drug effects , Male , Mice, Transgenic , Nerve Tissue Proteins/metabolism , Nestin/metabolism , Neural Stem Cells/drug effects , Neural Stem Cells/metabolism , Nuclear Proteins/metabolism , Orphan Nuclear Receptors/agonists , Protein Biosynthesis/drug effects , Up-Regulation/drug effects , tau Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...